US5138060A
(en)
*
|
1991-01-03 |
1992-08-11 |
Pfizer Inc. |
Process and intermediates for preparing azabicyclo(2.2.2)octan-3-imines
|
UA39168C2
(uk)
*
|
1991-06-20 |
2001-06-15 |
Пфайзер, Інк. |
Фторалкоксифенільні похідні піперидину або хінуклідину, що є антагоністами речовини p і фармацевтична композиція на їх основі
|
JP2656702B2
(ja)
*
|
1992-03-23 |
1997-09-24 |
ファイザー製薬株式会社 |
ペプチド性キヌクリジン
|
AU4224993A
(en)
*
|
1992-08-19 |
1994-03-15 |
Pfizer Inc. |
Substituted benzylamino nitrogen containing non-aromatic heterocycles
|
JP2656699B2
(ja)
*
|
1992-10-21 |
1997-09-24 |
ファイザー製薬株式会社 |
置換ベンジルアミノキヌクリジン
|
JP2656700B2
(ja)
*
|
1992-10-28 |
1997-09-24 |
ファイザー製薬株式会社 |
置換キヌクリジン誘導体
|
US5837711A
(en)
*
|
1992-10-28 |
1998-11-17 |
Pfizer Inc. |
Substituted quinuclidines as substance P antagonists
|
ATE194340T1
(de)
*
|
1992-12-10 |
2000-07-15 |
Pfizer |
Aminomethylen substituierte heterocyclische verbindungen und ihre verwendung alssubstanz p antagonisten
|
IL109646A0
(en)
*
|
1993-05-19 |
1994-08-26 |
Pfizer |
Heteroatom substituted alkyl benzylamino-quinuclidines
|
JP2822274B2
(ja)
*
|
1993-05-19 |
1998-11-11 |
ファイザー製薬株式会社 |
P物質拮抗剤としてのヘテロ原子置換アルキルベンジルアミノキヌクリジン類
|
US5393762A
(en)
*
|
1993-06-04 |
1995-02-28 |
Pfizer Inc. |
Pharmaceutical agents for treatment of emesis
|
ATE171945T1
(de)
*
|
1993-07-15 |
1998-10-15 |
Pfizer |
Benzyloxychinuclidine als substanz p antagonisten
|
US6083943A
(en)
*
|
1993-09-17 |
2000-07-04 |
Pfizer Inc |
Substituted azaheterocyclecarboxylic acid
|
DK0719253T3
(da)
*
|
1993-09-17 |
2004-07-26 |
Pfizer |
3-amino-5-carboxy-substituerede piperidiner og 3-amino-4-carboxy-substituerede pyrrolidiner som tachykininantagonister
|
EP0653208A3
(en)
*
|
1993-11-17 |
1995-10-11 |
Pfizer |
Substance P antagonists for the treatment or prevention of sunburn.
|
EP0659409A3
(en)
*
|
1993-11-23 |
1995-08-09 |
Pfizer |
Substance P antagonists for the inhibition of angiogenesis.
|
EP0655246A1
(en)
*
|
1993-11-30 |
1995-05-31 |
Pfizer Inc. |
Substance P antagonists for the treatment of disorders caused by helicobacter pylori or other spiral urease-positive gram-negative bacteria
|
FR2728165A1
(fr)
|
1994-12-19 |
1996-06-21 |
Oreal |
Utilisation d'un antagoniste de substance p pour le traitement des rougeurs cutanees d'origine neurogene
|
FR2728169A1
(fr)
|
1994-12-19 |
1996-06-21 |
Oreal |
Utilisation d'un antagoniste de substance p pour le traitement des prurits et des dysesthesies oculaires ou palpebrales
|
FR2728166A1
(fr)
|
1994-12-19 |
1996-06-21 |
Oreal |
Composition topique contenant un antagoniste de substance p
|
PE8798A1
(es)
*
|
1995-07-17 |
1998-03-02 |
Pfizer |
Procedimiento de separacion de los enantiomeros del 1-azabiciclo[2.2.2] octan-3-amina, 2-(difenilmetil) -n- [[2-metoxi-5-(1-metiletil) fenil] metil]
|
TW458774B
(en)
|
1995-10-20 |
2001-10-11 |
Pfizer |
Antiemetic pharmaceutical compositions
|
FR2741262B1
(fr)
|
1995-11-20 |
1999-03-05 |
Oreal |
Utilisation d'un antagoniste de tnf-alpha pour le traitement des rougeurs cutanees d'origine neurogene
|
MX9706944A
(es)
*
|
1996-09-12 |
1998-08-30 |
Pfizer |
Quinuclidinas sustituidas con tetrazolilo como antagonistas de la sustancia p.
|
NZ329807A
(en)
*
|
1997-04-23 |
2000-07-28 |
Pfizer |
NK-1 receptor antagonists and P receptor antagonists 2-Diarylmethyl-3-amino-1-azabicyclo[2.2.2]octane derivatives and amino substituted N-containing rings as agents for treating irritable bowel syndrome
|
AU781179B2
(en)
|
1999-11-03 |
2005-05-12 |
Albany Molecular Research, Inc. |
Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
|
US7163949B1
(en)
|
1999-11-03 |
2007-01-16 |
Amr Technology, Inc. |
4-phenyl substituted tetrahydroisoquinolines and use thereof
|
US7084152B2
(en)
|
2000-07-11 |
2006-08-01 |
Amr Technology, Inc. |
4-phenyl substituted tetrahydroisoquinolines therapeutic use thereof
|
DOP2002000332A
(es)
|
2001-02-14 |
2002-08-30 |
Warner Lambert Co |
Inhibidores de piridina de metaloproteinasas de la matriz
|
US6861526B2
(en)
*
|
2002-10-16 |
2005-03-01 |
Pfizer Inc. |
Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine
|
EP1778639B1
(en)
|
2004-07-15 |
2015-09-02 |
Albany Molecular Research, Inc. |
Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
|
WO2006123182A2
(en)
|
2005-05-17 |
2006-11-23 |
Merck Sharp & Dohme Limited |
Cyclohexyl sulphones for treatment of cancer
|
KR20080044840A
(ko)
|
2005-07-15 |
2008-05-21 |
에이엠알 테크놀로지, 인크. |
아릴- 및 헤테로아릴-치환된 테트라히드로벤자제핀, 및노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기위한 용도
|
US8293900B2
(en)
|
2005-09-29 |
2012-10-23 |
Merck Sharp & Dohme Corp |
Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
AU2007300627B2
(en)
|
2006-09-22 |
2012-02-16 |
Merck Sharp & Dohme Corp. |
Method of treatment using fatty acid synthesis inhibitors
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
AU2008204380B2
(en)
|
2007-01-10 |
2013-08-15 |
Msd Italia S.R.L. |
Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
|
WO2008090114A1
(en)
|
2007-01-24 |
2008-07-31 |
Glaxo Group Limited |
Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
|
CA2682727C
(en)
|
2007-04-02 |
2016-03-22 |
Banyu Pharmaceutical Co., Ltd. |
Indoledione derivative
|
EP2170076B1
(en)
|
2007-06-27 |
2016-05-18 |
Merck Sharp & Dohme Corp. |
4-carboxybenzylamino derivatives as histone deacetylase inhibitors
|
CA2717509A1
(en)
|
2008-03-03 |
2009-09-11 |
Tiger Pharmatech |
Tyrosine kinase inhibitors
|
US9156812B2
(en)
|
2008-06-04 |
2015-10-13 |
Bristol-Myers Squibb Company |
Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
|
UA105182C2
(ru)
|
2008-07-03 |
2014-04-25 |
Ньюрексон, Інк. |
Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
|
WO2010114780A1
(en)
|
2009-04-01 |
2010-10-07 |
Merck Sharp & Dohme Corp. |
Inhibitors of akt activity
|
MX2011011901A
(es)
|
2009-05-12 |
2012-01-20 |
Albany Molecular Res Inc |
Tetrahidroisoquinolinas aril, heteroaril, y heterociclo sustituidas y uso de las mismas.
|
CN102638982B
(zh)
|
2009-05-12 |
2015-07-08 |
百时美施贵宝公司 |
(S)-7-([1,2,4]三唑并[1,5-a]吡啶-6-基)-4-(3,4-二氯苯基)-1,2,3,4-四氢异喹啉的晶型及其用途
|
KR101830447B1
(ko)
|
2009-05-12 |
2018-02-20 |
알바니 몰레큘라 리써치, 인크. |
7-([1,2,4]트리아졸로[1,5-α]피리딘-6-일)-4-(3,4-디클로로페닐)-1,2,3,4-테트라하이드로이소퀴놀린 및 이의 용도
|
MX2012004377A
(es)
|
2009-10-14 |
2012-06-01 |
Merck Sharp & Dohme |
Piperidinas sustituidas que aumentan la actividad de p53 y sus usos.
|
WO2011163330A1
(en)
|
2010-06-24 |
2011-12-29 |
Merck Sharp & Dohme Corp. |
Novel heterocyclic compounds as erk inhibitors
|
EP3330377A1
(en)
|
2010-08-02 |
2018-06-06 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
|
EP2606134B1
(en)
|
2010-08-17 |
2019-04-10 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US8883801B2
(en)
|
2010-08-23 |
2014-11-11 |
Merck Sharp & Dohme Corp. |
Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
|
EP2613782B1
(en)
|
2010-09-01 |
2016-11-02 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as erk inhibitors
|
EP2615916B1
(en)
|
2010-09-16 |
2017-01-04 |
Merck Sharp & Dohme Corp. |
Fused pyrazole derivatives as novel erk inhibitors
|
ES2663009T3
(es)
|
2010-10-29 |
2018-04-10 |
Sirna Therapeutics, Inc. |
Inhibición de la expresión génica mediada por interferencia por ARN utilizando ácidos nucleicos de interferencia cortos (ANic)
|
WO2012087772A1
(en)
|
2010-12-21 |
2012-06-28 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
CN103732592A
(zh)
|
2011-04-21 |
2014-04-16 |
默沙东公司 |
胰岛素样生长因子-1受体抑制剂
|
WO2013063214A1
(en)
|
2011-10-27 |
2013-05-02 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
EP3919620A1
(en)
|
2012-05-02 |
2021-12-08 |
Sirna Therapeutics, Inc. |
Short interfering nucleic acid (sina) compositions
|
RU2660429C2
(ru)
|
2012-09-28 |
2018-07-06 |
Мерк Шарп И Доум Корп. |
Новые соединения, которые являются ингибиторами erk
|
JP6290237B2
(ja)
|
2012-11-28 |
2018-03-07 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
癌を処置するための組成物および方法
|
AR094116A1
(es)
|
2012-12-20 |
2015-07-08 |
Merck Sharp & Dohme |
Imidazopiridinas sustituidas como inhibidores de hdm2
|
EP2951180B1
(en)
|
2013-01-30 |
2018-05-02 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as hdm2 inhibitors
|
WO2015034925A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
WO2018071283A1
(en)
|
2016-10-12 |
2018-04-19 |
Merck Sharp & Dohme Corp. |
Kdm5 inhibitors
|
WO2019094311A1
(en)
|
2017-11-08 |
2019-05-16 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
US11993602B2
(en)
|
2018-08-07 |
2024-05-28 |
Merck Sharp & Dohme Llc |
PRMT5 inhibitors
|
US11981701B2
(en)
|
2018-08-07 |
2024-05-14 |
Merck Sharp & Dohme Llc |
PRMT5 inhibitors
|